Decorin as a multivalent therapeutic agent against cancer

Advanced Drug Delivery Reviews

Volumn 97, Issue , 2016, Pages 174-185

  Neill, Thomas ^a   Schaefer, Liliana ^b   Iozzo, Renato V ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Angiogenesis; Autophagy; Endothelial cells; Mitophagy; Receptor tyrosine kinases; Small leucine rich proteoglycan

Indexed keywords

AMINO ACIDS; BINS; CELL SIGNALING; CELLS; CYTOLOGY; ENZYMES; GLYCOPROTEINS; TUMORS;

ANGIOGENESIS; AUTOPHAGY; MITOPHAGY; PROTEOGLYCANS; RECEPTOR TYROSINE KINASE;

ENDOTHELIAL CELLS;

ANTINEOPLASTIC AGENT; BECLIN 1; CYTOKINE; DECORIN; PROTEOGLYCAN; TYROSINE KINASE RECEPTOR; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MET PROTEIN, HUMAN; SCATTER FACTOR RECEPTOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; AUTOPHAGY; CELL CYCLE ARREST; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTHELIUM CELL; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE ACTIVATION; MITOPHAGY; MORPHOGENESIS; MULTIGENE FAMILY; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SOLID TUMOR; ANIMAL; CHEMISTRY; GENE THERAPY; GENETICS; METABOLISM; NEOPLASMS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

ANIMALS; AUTOPHAGY; DECORIN; GENETIC THERAPY; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84957811354     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.10.016     Document Type: Review

References (191)

1. DeBerardinis R.J., Lum J.J., Hatzivassiliou G., Thompson C.B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008, 7:11-20.
2. Hahn W.C., Weinberg R.A. Rules for making human tumor cells. N. Engl. J. Med. 2002, 347:1593-1603.
3. Hanahan D., Winberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
4. Weigelt B., Bissell M.J. Unraveling the micronevironment influences on the normal mammary gland and breast cancer. Semin. Cancer Biol. 2008, 18:311-321.
5. Bissell M.J., Hines W.C. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat. Med. 2011, 17:320-329.
6. Rønnov-Jessen L., Bissell M.J. Breast cancer by proxy: can the microenvironment be both the cause and consequence?. Trends Mol. Med. 2009, 15:5-13.
7. Hanahan D., Coussens L.M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21:309-322.
8. Grahovac J., Wells A. Matrikine and matricellular regulators of EGF receptor signaling on cancer cell migration. Lab. Investig. 2014, 94:31-40.
9. Merline R., Nastase M.V., Iozzo R.V., Schaefer L. Small leucine-rich proteoglycans: multifunctional signaling effectors. Extracellular Matrix: Pathobiology and signaling 2012, 185-196. Walter de Gruytier Gmbh and Co., Berlin. N. Karamanos (Ed.).
10. Goldoni S., Iozzo R.V. Tumor microenvironment: modulation by decorin and related molecules harboring leucine-rich tandem motifs. Int. J. Cancer 2008, 123:2473-2479.
11. Iozzo R.V., Sanderson R.D. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J. Cell. Mol. Med. 2011, 15:1013-1031.
12. Theocharis A.D., Skandalis S.S., Neill T., Multhaupt H.A., Hubo M., Frey H., Gopal S., Gomes A., Afratis N., Lim H.C., Couchman J.R., Filmus J., Ralph D.S., Schaefer L., Iozzo R.V., Karamanos N.K. Insights into the key roles of proteoglycans in breast cancer biology and translational medicine. Biochim. Biophys. Acta 2015, 1855:276-300.
13. Schaefer L. Proteoglycans, key regulators of cell-matrix dynamics. Matrix Biol. 2014, 35:1-2.
14. Schaefer L., Iozzo R.V. Small leucine-rich proteoglycans, at the crossroad of cancer growth and inflammation. Curr. Opin. Genet. Dev. 2012, 22:56-57.
15. Iozzo R.V., Schaefer L. Proteoglycan form and function: a comprehensive nomenclature of proteoglycans. Matrix Biol. 2015, 42:11-55.
16. Scott P.G., McEwan P.A., Dodd C.M., Bergmann E.M., Bishop P.N., Bella J. Crystal structure of the dimeric protein core of decorin, the archetypal small leucine-rich repeat proteoglycan. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:15633-15638.
17. Goldoni S., Owens R.T., McQuillan D.J., Shriver Z., Sasisekharan R., Birk D.E., Campbell S., Iozzo R.V. Biologically active decorin is a monomer in solution. J. Biol. Chem. 2004, 279:6606-6612.
18. Islam M., Gor J., Perkins S.J., Ishikawa Y., Bãchinger H.S., Hohenester E. The concave face of decorin mediates reversible dimerization and collagen binding. J. Biol. Chem. 2013, 288:35526-35533.
19. Chen S., Young M.F., Chakravarti S., Birk D.E. Interclass small leucine-rich repeat proteoglycan interactions regulate collagen fibrillogenesis and corneal stromal assembly. Matrix Biol. 2014, 35:103-111.
20. Chen S., Birk D.E. The regulatory roles of small leucine-rich proteoglycans in extracellular matrix assembly. FEBS J. 2013, 280:2120-2137.
21. Zhang G., Chen S., Goldoni S., Calder B.W., Simpson H.C., Owens R.T., McQuillan D.J., Young M.F., Iozzo R.V., Birk D.E. Genetic evidence for the coordinated regulation of collagen fibrillogenesis in the cornea by decorin and biglycan. J. Biol. Chem. 2009, 284:8888-8897.
22. Reese S.P., Underwood C.J., Weiss J.A. Effects of decorin proteoglycan on fibrillogenesis, ultrastructure, and mechanics of type I collagen gels. Matrix Biol. 2013, 32:414-423.
23. Robinson P.S., Huang T.F., Kazam E., Iozzo R.V., Birk D.E., Soslowsky L.J. Influence of decorin and biglycan on mechanical properties of multiple tendons in knockout mice. J. Biomech. Eng. 2005, 127:181-185.
24. Zhang G., Ezura Y., Chervoneva I., Robinson P.S., Beason D.P., Carine E.T., Soslowsky L.J., Iozzo R.V., Birk D.E. Decorin regulates assembly of collagen fibrils and acquisition of biomechanical properties during tendon development. J. Cell. Biochem. 2006, 98:1436-1449.
25. Dunkman A.A., Buckley M.R., Mienaltowski M.J., Adams S.M., Thomas S.J., Kumar A., Beason D.P., Iozzo R.V., Birk D.E., Soslowsky L.J. The injury response of aged tendons in the absence of biglycan and decorin. Matrix Biol. 2014, 35:232-238.
26. Dunkman A.A., Buckley M.R., Mienaltowski M.J., Adams S.M., Thomas S.J., Satchell L., Kumar A., Pathmanathan L., Beason D.P., Iozzo R.V., Birk D.E., Soslowsky L.J. Decorin expression is important for age-related changes in tendon structure and mechanical properties. Matrix Biol. 2013, 32:3-13.
27. Järveläinen H., Sainio A., Wight T.N. Pivotal role for decorin in angiogenesis. Matrix Biol. 2015, 43:15-26.
28. Droguett R., Cabello-Verrugio C., Riquelme C., Brandan E. Extracellular proteoglycans modify TGF-β bio-availability attenuating its signaling during skeletal muscle differentiation. Matrix Biol. 2006, 25:332-341.
29. Curran C.S., Keely P.J. Breast tumor and stromal cell response to TGF-β and hypoxia in matrix deposition. Matrix Biol. 2013, 32:95-105.
30. Vial C., Gutierrez J., Santander C., Cabrera D., Brandan E. Decorin interacts with connective tissue growth factor (CTGF)/CCN2 by LRR12 inhibiting its biological activity. J. Biol. Chem. 2011, 286:24242-24252.
31. Neill T., Schaefer L., Iozzo R.V. Decorin, a guardian from the matrix. Am. J. Pathol. 2012, 181:380-387.
32. Neill T., Schaefer L., Iozzo R.V. Instructive roles of extracellular matrix on autophagy. Am. J. Pathol. 2014, 184:2146-2153.
33. Merline R., Moreth K., Beckmann J., Nastase M.V., Zeng-Brouwers J., Tralhão J.G., Lemarchand P., Pfeilschifter J., Schaefer R.M., Iozzo R.V., Schaefer L. Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and microRNA-21. Sci. Signal. 2011, 4. (ra75).
34. Frey T., Schroeder N., Manon-Jensen T., Iozzo R.V., Schaefer L. Biological interplay between proteoglycans and their innate immune receptors in inflammation. FEBS J. 2013, 280:2165-2179.
35. Järveläinen H., Puolakkainen P., Pakkanen S., Brown E.L., Höök M., Iozzo R.V., Sage H., Wight T.N. A role for decorin in cutaneous wound healing and angiogenesis. Wound Repair Regen. 2006, 14:443-452.
36. Nikolovska K., Renke J.K., Jungmann O., Grobe K., Iozzo R.V., Zamfir A.D., Seidler D.G. A decorin-deficient matrix affects skin chondroitin/dermatan sulfate levels and keratinocyte function. Matrix Biol. 2014, 35:91-102.
37. Merline R., Lazaroski S., Babelova A., Tsalastra-Greul W., Pfeilschifter J., Schluter K.D., Gunther A., Iozzo R.V., Schaefer R.M., Schaefer L. Decorin deficiency in diabetic mice: aggravation of nephropathy due to overexpression of profibrotic factors, enhanced apoptosis and mononuclear cell infiltration. J. Physiol. Pharmacol. 2009, 60(Suppl. 4):5-13.
38. Wu Z., Horgan C.E., Carr O., Owens R.T., Iozzo R.V., Lechner B.E. Biglycan and decorin differentially regulate signaling in the fetal membranes. Matrix Biol. 2014, 35:266-275.
39. Bolton K., Segal D., McMillan J., Jowett J., Heilbronn L., Abberton K., Zimmet P., Chisholm D., Collier G., Walder K. Decorin is a secreted protein associated with obesity and type 2 diabetes. Int. J. Obes. 2008, 32:1113-1121.
40. Marchica C.L., Pinelli V., Borges M., Zummer J., Narayanan V., Iozzo R.V., Ludwig M.S. A role for decorin in a murine model of allergen-induced asthma. Am. J. Physiol. Lung Cell. Mol. Physiol. 2011, 300:863-873.
41. Bocian C., Urbanowitz A.K., Owens R.T., Iozzo R.V., Gotte M., Seidler D.G. Decorin potentiates interferon-gamma activity in a model of allergic inflammation. J. Biol. Chem. 2013, 288:12699-12711.
42. Seidler D.G., Mohamed N.A., Bocian C., Stadtmann A., Hermann S., Schäfers K., Schäfers M., Iozzo R.V., Zarbock A., Götte M. The role for decorin in delayed-type hypersensitivity. J. Immunol. 2011, 187:6108-6199.
43. Baghy K., Dezsó K., László V., Fullár A., Péterfia B., Paku S., Nagy P., Schaff Z., Iozzo R.V., Kovalszky I. Ablation of the decorin gene enhances experimental hepatic fibrosis and impairs hepatic healing in mice. Lab. Investig. 2011, 91:439-451.
44. Brandan E., Cabello-Verrugio C., Vial C. Novel regulatory mechanisms for the proteoglycans decorin and biglycan during muscle formation and muscular dystrophy. Matrix Biol. 2008, 27:700-708.
45. Brandan E., Gutierrez J. Role of skeletal muscle proteoglycans during myogenesis. Matrix Biol. 2013, 32:289-297.
46. Weis S.M., Zimmerman S.D., Shah M., Covell J.W., Omens J.H., Ross J., Dalton N., Jones Y., Reed C.C., Iozzo R.V., McCulloch A.D. A role for decorin in the remodeling of myocardial infarction. Matrix Biol. 2005, 24:313-324.
47. Zoeller J.J., Pimtong W., Corby H., Goldoni S., Iozzo A.E., Owens R.T., Ho S.-Y., Iozzo R.V. A central role for decorin during vertebrate convergent extension. J. Biol. Chem. 2009, 284:11728-11737.
48. Xu Y.-Z., Zhang Y.-H., Zhang Y.-W., Hong B., Liu J.-M. Dynamic reduction of plasma decorin following ischemic stroke: a pilot study. Neurochem. Res. 2012, 37:1843-1848.
49. Schaefer L. Small leucine-rich proteoglycans in kidney disease. J. Am. Soc. Nephrol. 2011, 22:1200-1207.
50. Nastase M.V., Iozzo R.V., Schaefer L. Key roles for the small leucine-rich proteoglycans in renal and pulmonary pathophysiology. Biochim. Biophys. Acta 2014, 1840:2460-2470.
51. Schaefer L. Extracellular matrix molecules: endogenous danger signals as new drug targets in kidney diseases. Curr. Opin. Pharmacol. 2010, 10:185-190.
52. Ichii M., Frank M.B., Iozzo R.V., Kincade P.W. The canonical Wnt pathway shapes niches supportive of hematopoietic stem/progenitor cells. Blood 2012, 119:1683-1692.
53. Nyman M.C., Sainio A.O., Pennanen M.M., Lund R.J., Vuorikoski S., Sundström J.T., Järveläinen H.T. Decorin in human colon cancer: localization in vivo and effect on cancer cell behavior in vitro. J. Histochem. Cytochem. 2015, 63:710-720.
54. Neill T., Schaefer L., Iozzo R.V. An oncosuppressive role for decorin. Mol. Cell. Oncol. 2015, 2.
55. Troup S., Njue C., Kliewer E.V., Parisien M., Roskelley C., Chakravarti S., Roughley P.J., Murphy L.C., Watson P.H. Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin. Cancer Res. 2003, 9:207-214.
56. Goldoni S., Seidler D.G., Heath J., Fassan M., Baffa R., Thakur M.L., Owens R.A., McQuillan D.J., Iozzo R.V. An anti-metastatic role for decorin in breast cancer. Am. J. Pathol. 2008, 173:844-855.
57. Reed C.C., Waterhouse A., Kirby S., Kay P., Owens R.A., McQuillan D.J., Iozzo R.V. Decorin prevents metastatic spreading of breast cancer. Oncogene 2005, 24:1104-1110.
58. Matsumine A., Shintani K., Kusuzaki K., Matsubara T., Satonaka H., Wakabayashi T., Iino T., Uchida A. Expression of decorin, a small leucine-rich proteoglycan, as a prognostic factor in soft tissue tumors. J. Surg. Oncol. 2007, 96:411-418.
59. Iozzo R.V., Buraschi S., Genua M., Xu S.-Q., Solomides C.C., Peiper S.C., Gomella L.G., Owens R.T., Morrione A. Decorin antagonizes IGF receptor I (IGF-IR) function by interfering with IGF-IR activity and attenuating downstream signaling. J. Biol. Chem. 2011, 286:34712-34721.
60. Kristensen I.B., Pedersen L., Ro T.D., Christensen J.H., Lyng M.B., Rasmussen L.M., Ditzel H.J., Borset M., Abildgaard N. Decorin is down-regulated in multiple myeloma and MGUS bone marrow plasma and inhibits HGF-induced myeloma plasma cell viability and migration. Eur. J. Haematol. 2013, 91:196-200.
61. Wu I.-C., Wu D.-C., Huang C.-C., Lin H.-S., Chen Y.-K., Tsai H.-J., Lu C.-Y., Chou S.-H., Chou Y.-P., Li L.-H., Tai S.-Y., Wu M.-T. Plasma decorin predicts the presence of esophageal squamous cell carcinoma. Int. J. Cancer 2010, 127:2138-2146.
62. Bozoky B., Savchenko A., Guven H., Ponten F., Klein G., Szekely L. Decreased decorin expression in the tumor microenvironment. Cancer Med. 2014, 3:485-491.
63. Li X., Pennisi A., Yaccoby S. Role of decorin in the antimyeloma effects of osteoblasts. Blood 2008, 112:159-168.
64. Sainio A., Nyman M., Lund R., Vuorikoski S., Boström P., Laato M., Boström P.J., Järveläinen H. Lack of decorin expression by human bladder cancer cells offers new tools in the therapy of urothelial malignancies. PLoS ONE 2013, 8.
65. Boström P., Sainio A., Kakko T., Savontaus M., Söderström M., Järveläinen H. Localization of decorin gene expression in normal human breast tissue and in benign and malignant tumors of the human breast. Histochem. Cell Biol. 2013, 139:161-171.
66. Salomäki H.H., Sainio A.O., Söderström M., Pakkanen S., Laine J., Järveläinen H.T. Differential expression of decorin by human malignant and benign vascular tumors. J. Histochem. Cytochem. 2008, 56:639-646.
67. Henke A., Grace O.C., Ashley G.R., Stewart G.D., Riddick A.C.P., Yeun H., O'Donnell M., Anderson R.A., Thomson A.A. Stromal expression of decorin, semaphorin6D, SPARC, Sprouty 1 and Tsukushi in developing prostate and decreased levels of decorin in prostate cancer. PLoS ONE 2012, 7.
68. Horvath Z., Kovalszky I., Fullar A., Kiss K., Schaff Z., Iozzo R.V., Baghy K. Decorin deficiency promotes hepatic carcinogenesis. Matrix Biol. 2014, 35:194-205.
69. Duncan M.B. Extracellular matrix transcriptome dynamics in hepatocellular carcinoma. Matrix Biol. 2013, 32:393-398.
70. Iozzo R.V., Bolender R.P., Wight T.N. Proteoglycan changes in the intercellular matrix of human colon carcinoma. Lab. Investig. 1982, 47:124-138.
71. Adany R., Iozzo R.V. Hypomethylation of the decorin proteoglycan gene in human colon cancer. Biochem. J. 1991, 276:301-306.
72. Adany R., Heimer R., Caterson B., Sorrell J.M., Iozzo R.V. Altered expression of chondroitin sulfate proteoglycan in the stroma of human colon carcinoma. Hypomethylation of PG-40 gene correlates with increased PG-40 content and mRNA levels. J. Biol. Chem. 1990, 265:11389-11396.
73. Danielson K.G., Baribault H., Holmes D.F., Graham H., Kadler K.E., Iozzo R.V. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J. Cell Biol. 1997, 136:729-743.
74. Bi X., Tong C., Dokendorff A., Banroft L., Gallagher L., Guzman-Hartman G., Iozzo R.V., Augenlicht L.H., Yang W. Genetic deficiency of decorin causes intestinal tumor formation through disruption of intestinal cell maturation. Carcinogenesis 2008, 29:1435-1440.
75. Bi X., Pohl N.M., Yang G.R., Gou Y., Guzman G., Kajdacsy-Balla A., Iozzo R.V., Yang W. Decorin-mediated inhibition of colorectal cancer growth and migration is associated with E-cadherin in vitro and in mice. Carcinogenesis 2012, 33:326-330.
76. Iozzo R.V., Chakrani F., Perrotti D., McQuillan D.J., Skorski T., Calabretta B., Eichstetter I. Cooperative action of germline mutations in decorin and p53 accelerates lymphoma tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:3092-3097.
77. Araki K., Wakabayashi H., Shintani K., Morikawa J., Matsumine A., Kusuzaki K., Sudo A., Uchida A. Decorin suppresses bone metastasis in a breast cancer cell line. Oncology 2009, 77:92-99.
78. Grant D.S., Yenisey C., Rose R.W., Tootell M., Santra M., Iozzo R.V. Decorin suppresses tumor cell-mediated angiogenesis. Oncogene 2002, 21:4765-4777.
79. Neill T., Painter H., Buraschi S., Owens R.T., Lisanti M.P., Schaefer L., Iozzo R.V. Decorin antagonizes the angiogenic network. Concurrent inhibition of Met, hypoxia inducible factor-1α and vascular endothelial growth factor A and induction of thrombospondin-1 and TIMP3. J. Biol. Chem. 2012, 287:5492-5506.
80. Shintani K., Matsumine A., Kusuzaki K., Morikawa J., Matsubara T., Wakabayashi T., Araki K., Satonaka H., Wakabayashi H., Lino T., Uchida A. Decorin suppresses lung metastases of murine osteosarcoma. Oncol. Rep. 2008, 19:1533-1539.
81. Stock C., Jungmann O., Seidler D.G. Decorin and chondroitin-6 sulfate inhibit B16V melanoma cell migration and invasion by cellular acidification. J. Cell. Physiol. 2011, 226:2641-2650.
82. Santra M., Skorski T., Calabretta B., Lattime E.C., Iozzo R.V. De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:7016-7020.
83. De Luca A., Santra M., Baldi A., Giordano A., Iozzo R.V. Decorin-induced growth suppression is associated with upregulation of p21, an inhibitor of cyclin-dependent kinases. J. Biol. Chem. 1996, 271:18961-18965.
84. Santra M., Mann D.M., Mercer E.W., Skorski T., Calabretta B., Iozzo R.V. Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. J. Clin. Invest. 1997, 100:149-157.
85. Reed C.C., Gauldie J., Iozzo R.V. Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin. Oncogene 2002, 21:3688-3695.
86. Tralhão J.G., Schaefer L., Micegova M., Evaristo C., Schönherr E., Kayal S., Veiga-Fernandes H., Danel C., Iozzo R.V., Kresse H., Lemarchand P. In vivo selective and distant killing of cancer cells using adenovirus-mediated decorin gene transfer. FASEB J. 2003, 17:464-466.
87. Seidler D.G., Goldoni S., Agnew C., Cardi C., Thakur M.L., Owens R.A., McQuillan D.J., Iozzo R.V. Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptor function and triggering apoptosis via caspase-3 activation. J. Biol. Chem. 2006, 281:26408-26418.
88. Buraschi S., Neill T., Owens R.T., Iniguez L.A., Purkins G., Vadigepalli R., Evans B., Schaefer L., Peiper S.C., Wang Z., Iozzo R.V. Decorin protein core affects the global gene expression profile of the tumor microenvironment in a triple-negative orthotopic breast carcinoma xenograft model. PLoS ONE 2012, 7.
89. Buraschi S., Pal N., Tyler-Rubinstein N., Owens R.T., Neill T., Iozzo R.V. Decorin antagonizes Met receptor activity and downregulates β-catenin and Myc levels. J. Biol. Chem. 2010, 285:42075-42085.
90. Xu W., Neill T., Yang Y., Hu Z., Cleveland E., Wu Y., Hutten R., Xiao X., Stock S.R., Shevrin D., Kaul K., Brendler C., Iozzo R.V., Seth P. The systemic delivery of an oncolytic adenovirus expressing decorin inhibits bone metastasis in a mouse model of human prostate cancer. Gene Ther. 2015, 22:31-40.
91. Yang Y., Xu W.W., Neill T., Hu Z., Wang C.H., Xiao X., Stock S., Guise T., Yun C.O., Brendler C.B., Iozzo R.V., Seth P. Systemic delivery of an oncolytic adenovirus expressing decorin for the treatment of breast cancer bone metastases. Hum. Gene Ther. 2015, (in press).
92. Iozzo R.V., Goldoni S., Berendsen A., Young M.F. Small leucine-rich proteoglycans. Extracellular Matrix: An overview 2011, 197-231. Springer. R.P. Mecham (Ed.).
93. Scholzen T., Solursh M., Suzuki S., Reiter R., Morgan J.L., Buchberg A.M., Siracusa L.D., Iozzo R.V. The murine decorin. Complete cDNA cloning, genomic organization, chromosomal assignment and expression during organogenesis and tissue differentiation. J. Biol. Chem. 1994, 269:28270-28281.
94. Fernandez-Zapico M.E., Ellenrieder V. NFAT transcription factors, the potion mediating "Dr.Jekyll-Mr. Hyde" transformation of the TGFβ pathway in cancer cells. Cell Cycle 2010, 9:3838-3839.
95. Neill T., Schaefer L., Iozzo R.V. Decoding the matrix: instructive roles of proteoglycan receptors. Biochemistry 2015, 54:4583-4598.
96. Khan G.A., Girish G.V., Lala N., DiGuglielmo G.M., Lala P.K. Decorin is a novel VEGFR-2-binding antagonist for the human extravillous trophoblast. Mol. Endocrinol. 2011, 25:1431-1443.
97. Kalamajski S., Aspberg A., Oldberg Å. The decorin sequence SYIRIADTNIT binds collagen type I. J. Biol. Chem. 2007, 282:16062-16067.
98. Chen S., Sun M., Meng X., Iozzo R.V., Kao W.W.Y., Birk D.E. Pathophysiological mechanisms of autosomal dominant congenital stromal corneal dystrophy. C-terminal-truncated decorin results in abnormal matrix assembly and altered expression of small leucine-rich proteoglycans. Am. J. Pathol. 2011, 179:2409-2419.
99. Chen S., Sun M., Iozzo R.V., Kao W.W., Birk D.E. Intracellularly-retained decorin lacking the C-terminal ear repeat causes ER stress: a cell-based etiological mechanism for congenital stromal corneal dystrophy. Am. J. Pathol. 2013, 183:247-256.
100. Seidler D.G. The galactosaminoglycan-containing decorin and its impact on diseases. Curr. Opin. Struct. Biol. 2012, 22:578-582.
101. Rühland C., Schönherr E., Robenek H., Hansen U., Iozzo R.V., Bruckner P., Seidler D.G. The glycosaminoglycan chain of decorin plays an important role in collagen fibril formation at the early stages of fibrillogenesis. FEBS J. 2007, 274:4246-4255.
102. Theocharis A.D., Tzanakakis G., Karamanos N.K. Proteoglycans in health and disease: novel proteoglycan roles in malignancy and their pharmacological targeting. FEBS J. 2010, 277:3904-3923.
103. Morrione A., Neill T., Iozzo R.V. Dichotomy of decorin activity on the insulin-like growth factor-I system. FEBS J. 2013, 280:2138-2149.
104. Metalli D., Lovat F., Tripodi F., Genua M., Xu S.-Q., Spinelli M., Alberghina L., Vanoni M., Baffa R., Gomella L.G., Iozzo R.V., Morrione A. The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin. Am. J. Pathol. 2010, 176:2997-3006.
105. Morcavallo A., Buraschi S., Xu S.-Q., Belfiore A., Schaefer L., Iozzo R.V., Morrione A. Decorin differentially modulates the activity of insulin receptor isoform A ligands. Matrix Biol. 2014, 35:82-90.
106. Skandalis S.S., Afratis N., Smirlaki G., Nikitovic D., Theocharis A.D., Tzanakakis G.N., Karamanos N.K. Cross-talk between estradiol receptor and EGFR/IGF-IR signaling pathways in estrogen-responsive breast cancers: focus on the role and impact of proteoglycans. Matrix Biol. 2014, 35:182-193.
107. Schaefer L. Complexity of danger: the diverse nature of damage-associated molecular patterns. J. Biol. Chem. 2014, 289:35237-35245.
108. Moreth K., Frey H., Hubo M., Zeng-Brouwers J., Nastase M.V., Hsieh L.T., Haceni R., Pfeilschifter J., Iozzo R.V., Schaefer L. Biglycan-triggered TLR-2- and TLR-4-signaling exacerbates the pathophysiology of ischemic acute kidney injury. Matrix Biol. 2014, 35:143-151.
109. Zeng-Brouwers J., Beckmann J., Nastase M.V., Iozzo R.V., Schaefer L. De novo expression of circulating biglycan evokes an innate inflammatory tissue response via MyD88/TRIF pathways. Matrix Biol. 2014, 35:132-142.
110. Hsieh L.T., Nastase M.V., Zeng-Brouwers J., Iozzo R.V., Schaefer L. Soluble biglycan as a biomarker of inflammatory renal diseases. Int. J. Biochem. Cell Biol. 2014, 54C:223-235.
111. Santra M., Reed C.C., Iozzo R.V. Decorin binds to a narrow region of the epidermal growth factor (EGF) receptor, partially overlapping with but distinct from the EGF-binding epitope. J. Biol. Chem. 2002, 277:35671-35681.
112. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 2002, 110:669-672.
113. Zhu J.-X., Goldoni S., Bix G., Owens R.A., McQuillan D., Reed C.C., Iozzo R.V. Decorin evokes protracted internalization and degradation of the EGF receptor via caveolar endocytosis. J. Biol. Chem. 2005, 280:32468-32479.
114. Moreth K., Iozzo R.V., Schaefer L. Small leucine-rich proteoglycans orchestrate receptor crosstalk during inflammation. Cell Cycle 2012, 11:2084-2091.
115. Goldoni S., Humphries A., Nyström A., Sattar S., Owens R.T., McQuillan D.J., Ireton K., Iozzo R.V. Decorin is a novel antagonistic ligand of the Met receptor. J. Cell Biol. 2009, 185:743-754.
116. Schlessinger J. Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 2004, 306:1506-1507.
117. Lemmon M.A., Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010, 141:1117-1134.
118. Moscatello D.K., Santra M., Mann D.M., McQuillan D.J., Wong A.J., Iozzo R.V. Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor. J. Clin. Invest. 1998, 101:406-412.
119. Iozzo R.V., Moscatello D., McQuillan D.J., Eichstetter I. Decorin is a biological ligand for the epidermal growth factor receptor. J. Biol. Chem. 1999, 274:4489-4492.
120. Csordás G., Santra M., Reed C.C., Eichstetter I., McQuillan D.J., Gross D., Nugent M.A., Hajnóczky G., Iozzo R.V. Sustained down-regulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumor growth in vivo. J. Biol. Chem. 2000, 275:32879-32887.
121. Santra M., Eichstetter I., Iozzo R.V. An anti-oncogenic role for decorin: downregulation of ErbB2 leads to growth suppression and cytodifferentiation of mammary carcinoma cells. J. Biol. Chem. 2000, 275:35153-35161.
122. Minor K.H., Bournat J.C., Toscano N., Giger R.J., Davies S.J.A. Decorin, erythroblastic leukaemia viral oncogene homologue B4 and signal transducer and activator of transcription 3 regulation of semaphorin 3A in central nervous system scar tissue. Brain 2011, 134:1140-1155.
123. 2+ in A431 cells. J. Biol. Chem. 1998, 273:3121-3124.
124. Abulrob A., Giuseppin S., Andrade M.F., McDermid A., Moreno M., Stanimirovic D. Interactions of EGFR and caveolin-1 in human glioblastoma cells: evidence that tyrosine phosphorylation regulates EGFR association with caveolae. Oncogene 2004, 23:6967-6979.
125. Aberle H., Bauer A., Stappert J., Kispert A., Kemler R. β-catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 1997, 16:3797-3804.
126. Danilkovitch-Miagkova A., Miagkov A., Skeel A., Nakaigawa N., Zbar B., Leonard E.J. Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the β-catenin pathway. Mol. Cell. Biol. 2001, 21:5857-5868.
127. Clevers H. Wnt/β-catenin signaling in development and disease. Cell 2006, 127:469-480.
128. Monga S.P.S., Mars W.M., Pediaditakis P., Bell A., Mulé K., Bowen W.C., Wang X., Zarnegar R., Michalopoulos G.K. Hepatocyte growth factor induces Wnt-independent nuclear translocation of β-catenin after MET-β-catenin dissociation in hepatocytes. Cancer Res. 2008, 62:2064-2071.
129. Rasola A., Fassetta M., De Bacco F., D'Alessandro L., Gramaglia D., Di Renzo M.G., Comoglio P.M. A positive feedback loop between hepatocyte growth factor receptor and β-catenin sustains colorectal cancer cell invasive growth. Oncogene 2007, 26:1078-1087.
130. Finch A.J., Soucek L., Junttila M.R., Swigart L.B., Evan G.I. Acute overexpression of Myc in intestinal epithelium recapitulates some but not all the changes elicited by Wnt/β-catenin pathway activation. Mol. Cell. Biol. 2009, 29:5306-5315.
131. Herynk M.H., Tsan R., Radinsky R., Gallick G.E. Activation of c-Met in colorectal carcinoma cells leads to constitutive association of tyrosine-phosphorylated β-catenin. Clin. Exp. Metastasis 2003, 20:291-300.
132. Neill T., Jones H.R., Crane-Smith Z., Owens R.T., Schaefer L., Iozzo R.V. Decorin induces rapid secretion of thrombospondin-1 in basal breast carcinoma cells via inhibition of Ras homolog gene family, member A/Rho-associated coiled-coil containing protein kinase 1. FEBS J. 2013, 280:2353-2368.
133. Murphy-Ullrich J.E., Sage E.H. Revisiting the matricellular concept. Matrix Biol. 2014, 37:1-14.
134. Wallace D.M., Murphy-Ullrich J.E., Downs J.C., O'Brien C.J. The role of matricellular proteins in glaucoma. Matrix Biol. 2014, 37:174-182.
135. Resovi A., Pinessi D., Chiorino G., Taraboletti G. Current understanding of the thrombospondin-1 interactome. Matrix Biol. 2014, 37:83-91.
136. Rogers N.M., Sharifi-Sanjani M., Csanyi G., Pagano P.J., Isenberg J.S. Thrombospondin-1 and CD47 regulation of cardiac, pulmonary and vascular responses in health and disease. Matrix Biol. 2014, 37:92-101.
137. Duquette M., Nadler M., Okuhara D., Thompson J., Shuttleworth T., Lawler J. Members of the thrombospondin gene family bind stromal interaction molecule 1 and regulate calcium channel activity. Matrix Biol. 2014, 37:15-24.
138. Soto-Pantoja D.R., Shih H.B., Maxhimer J.B., Cook K.L., Ghosh A., Isenberg J.S., Roberts D.D. Thrombospondin-1 and CD47 signaling regulate healing of thermal injury in mice. Matrix Biol. 2014, 37:25-34.
139. DeCarvalho S. Angiokines, angiogenesis and angiolymphoproliferative syndromes (ALPS). Angiology 1983, 34:231-243.
140. Relaix F., Weng X., Marazzi G., Yang E., Copeland N., Jenkins N., Spence S.E., Sassoon D. Pw1, a novel zinc finger gene implicated in the myogenic and neuronal lineages. Dev. Biol. 1996, 177:383-396.
141. Kim J., Ashworth L., Branscomb E., Stubbs L. The human homolog of a mouse-imprinted gene, Peg3, maps to a zinc finger gene-rich region of human chromosome 19q13.4. Genome Res. 1997, 7:532-540.
142. Kuroiwa Y., Kaneko-Ishino T., Kagitani F., Kohda T., Li L.-L., Tada M., Suzuki R., Yokoyama M., Shiroishi T., Wakana S., Barton S.C., Ishino F., Surani M.A. Peg3 imprinted gene on proximal chromosome 7 encodes for a zinc finger protein. Nat. Genet. 1996, 12:186-190.
143. Thiaville M.M., Huang J.M., Kim H., Ekram M.B., Roh T.-Y., Kim J. DNA-binding motif and target genes of the imprinted transcription factor PEG3. Gene 2013, 512:314-320.
144. Besson V., Smeriglio P., Wegener A., Relaix F., Nait Oumesmar B., Sassoon D.A., Marazzi G. PW1 gene/paternally expressed gene 3 (PW1/Peg3) identifies multiple adult stem and progenitor cell populations. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:11470-11475.
145. Bonfanti C., Rossi G., Tedesco F.S., Giannotta M., Benedetti S., Tonlorenzi R., Antonini S., Marazzi G., Dejana E., Sassoon D., Cossu G., Messina G. PW1/Peg3 expression regulates key properties that determine mesoangioblast stem cell competence. Nat. Commun. 2015, 6:6364.
146. Relaix F., Wei X., Li W., Pan J., Lin Y., Bowtell D.D., Sasoon D.A., Wu X. Pw1/Peg3 is a potential cell death mediator and cooperates with Siah1a in p53-mediated apoptosis. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:2105-2110.
147. Johnson M.D., Wu X., Aithmitti N., Morrison R.S. Peg3/Pw1 is a mediator between p53 and Bax in DNA damage-induced neuronal death. J. Biol. Chem. 2002, 277:23000-23007.
148. Yamaguchi A., Taniguchi M., Hori O., Ogawa S., Tojo N., Matsuoka N., Miyake S., Kasai K., Sugimoto H., Tamatani M., Yamashita T., Yamashita T., Tohyama M. Peg3/Pw1 is involved in p53-mediated cell death pathway in brain ischemia/hypoxia. J. Biol. Chem. 2002, 277:623-629.
149. Deng Y., Wu X. Peg3/Pw1 promotes p53-mediated apoptosis by inducing Bax translocation from cytosol to mitochondria. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:12050-12055.
150. Coletti D., Yang E., Marazzi G., Sassoon D. TNFalpha inhibits skeletal myogenesis through a PW1-dependent pathway by recruitment of caspase pathways. EMBO J. 2002, 21:631-642.
151. Li L.-L., Keverne E.B., Aparicio S.A., Ishino F., Barton S.C., Surani M.A. Regulation of maternal behavior and offspring growth by paternally expressed Peg3. Science 1999, 284:330-333.
152. Champagne F.A., Curley J.P., Swaney W.T., Hasen N.S., Keverne E.B. Paternal influence on female behavior: the role of Peg3 in exploration, olfaction, and neuroendocrine regulation of maternal behavior of female mice. Behav. Neurosci. 2009, 123:469-480.
153. Nye M.D.H.C., Huang Z., Vidal A.C., Wang F., Overcash F., Smith J.S., Vasquez B., Hernandez B., Swai B., Oneko O., Mlay P., Obure J., Gammon M.D., Bartlett J.A., Murphy S.K. Association between methylation of paternally expressed gene 3 (PEG3), cervical intraepithelial neoplasia and invasive cervical cancer. PLoS ONE 2013, 8.
154. Dowdy S.C., Gostout B.S., Shridhar V., Wu X., Smith D.I., Podratz K.C., Jiang S.-W. Biallelic methylation and silencing of paternally expressed gene 3 (PEG3) in gynecologic cancer cell lines. Gynecol. Oncol. 2005, 99:126-134.
155. Feng W., Marquez R.T., Lu Z., Liu J., Lu K.H., Issa J.-P.J., Fishman D.M., Yu Y., Bast R.C. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer 2008, 112:1489-1502.
156. Maegawa S., Yoshioka H., Itaba N., Kubota N., Nishihara S., Shirayoshi Y., Nanba E., Oshimura M. Epigenetic silencing of PEG3 gene expression in human glioma cell lines. Mol. Carcinog. 2001, 31:1-9.
157. Kohda T., Asai A., Kuroiwa Y., Kobayashi S., Aisaka K., Nagashima G., Yoshida M.C., Kondo Y., Kagiyama N., Kirino T., Kaneko-Ishino T., Ishino F. Tumour suppressor activity of human imprinted gene PEG3 in a glioma cell line. Genes Cells 2001, 6:237-247.
158. Jiang X., Yu Y., Yang H.W., Agar N.Y.R., Frado L., Johnson M.D. The imprinted gene PEG3 inhibits Wnt signaling and regulates glioma growth. J. Biol. Chem. 2010, 285:8472-8480.
159. Buraschi S., Neill T., Goyal A., Poluzzi C., Smythies J., Owens R.T., Schaefer L., Torres A., Iozzo R.V. Decorin causes autophagy in endothelial cells via Peg3. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E2582-E2591.
160. Mizushima N., Levine B. Autophagy in mammalian development and differentiation. Nat. Cell Biol. 2010, 12:823-830.
161. He C., Klionsky D.J. Regulation mechanisms and signaling pathways of autophagy. Annu. Rev. Genet. 2009, 43:67-93.
162. Neill T., Torres A.T., Buraschi S., Iozzo R.V. Decorin has an appetite for endothelial cell autophagy. Autophagy 2013, 9:1626-1628.
163. Pattingre S., Levine B. Bcl-2 inhibition of autophagy: A new route to cancer?. Cancer Res. 2006, 66:2885-2888.
164. Goyal A., Neill T., Owens R.T., Schaefer L., Iozzo R.V. Decorin activates AMPK, an energy sensor kinase, to induce autophagy in endothelial cells. Matrix Biol. 2014, 34:46-54.
165. Neill T., Torres A., Buraschi S., Owens R.T., Hoek J., Baffa R., Iozzo R.V. Decorin induces mitophagy in breast carcinoma cells via peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) and mitostatin. J. Biol. Chem. 2014, 289:4952-4968.
166. Vecchione A., Fassan M., Anesti V., Morrione A., Goldoni S., Baldassarre G., Byrne D., D'Arca D., Palazzo J.P., Lloyd J., Scorrano L., Gomella L.G., Iozzo R.V., Baffa R. MITOSTATIN, a putative tumor suppressor on chromosome 12q24.1, is downregulated in human bladder and breast cancer. Oncogene 2009, 28:257-269.
167. Fassan M., D'Arca D., Letko J., Vecchione A., Gardiman M.P., McCue P., Wildemore B., Rugge M., Shupp-Byrne D., Gomella L.G., Morrione A., Iozzo R.V., Baffa R. Mitostatin is down-regulated in human prostate cancer and suppresses the invasive phenotype of prostate cancer cells. PLoS ONE 2011, 6.
168. Cerqua C., Anesti V., Pyakurel A., Liu D., Naon D., Wiche G., Baffa R., Dimmer K.S., Scorrano L. Trichoplein/mitostatin regulates endoplasmic reticulum-mitochondria juxtaposition. EMBO Rep. 2010, 11:854-860.
169. Ventura-Clapier R., Garnier A., Veksler W. Transcriptional control of mitochondrial biogenesis: the central role of PGC-1α. Cardiovasc. Res. 2008, 79:208-217.
170. Haq R., Shoag J., Andreu-Perez P., Yokoyama S., Edelman H., Rowe G.C., Frederick D.T., Hurley A.D., Nellore A., Kung A.L., Wargo J.A., Song J.S., Fisher D.E., Arany Z., Widlund H.R. Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell 2013, 23:302-315.
171. Vazquez F., Lim J.-H., Chim H., Bhalla K., Girnun G., Pierce K., Clish C.B., Granter S.R., Widlund H.R., Spiegelman B.M., Puigserver P. PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell 2013, 23:287-301.
172. Levine B., Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008, 132:27-42.
173. Dagda R., Cherra S.J.I., Kulich S.M., Tandon A., Park D., Chu C.T. Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission. J. Biol. Chem. 2009, 284:13843-13855.
174. Kubli D.A., Gustafsson Å.B. Mitochondria and mitophagy: the yin and yang of cell death control. Circ. Res. 2012, 111:1208-1221.
175. Staropoli J.F., McDermott C., Martinat C., Schulman B., Demireva E., Abeliovich A. Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 2003, 37:735-749.
176. Narendra D., Walker J.E., Youle R. Mitochondrial quality control mediated by PINK1 and Parkin: links to Parkinsonism. Cold Spring Harb. Perspect. Biol. 2012, 4.
177. Kane L.A., Lazarou M., Fogel A.I., Li Y., Yamano K., Sarraf S.A., Banerjee S., Youle R.J. PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity. J. Cell Biol. 2014, 205:143-153.
178. Koyano F., Okatsu K., Kosako H., Tamura Y., Go E., Kimura M., Kimura Y., Tsuchiya H., Yoshihara H., Hirokawa T., Endo T., Fon E.A., Trempe J.F., Saeki Y., Tanaka K., Matsuda N. Ubiquitin is phosphorylated by PINK1 to activate Parkin. Nature 2014, 510:162-166.
179. Matsuda N., Sato S., Shiba K., Okatsu K., Saisho K., Gautier C.A., Sou Y.S., Saiki S., Kawajiri S., Sato F., Kimura M., Komatsu M., Hattori N., Tanaka K. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J. Cell Biol. 2010, 189:211-221.
180. Iguchi M., Kujuro Y., Okatsu K., Koyano F., Kosako H., Kimura M., Suzuki N., Uchiyama S., Tanaka K., Matsuda N. Parkin-catalyzed ubiquitin-ester transfer is triggered by PINK1-dependent phosphorylation. J. Biol. Chem. 2013, 288:22019-22032.
181. Geisler S., Holmstrom K.M., Skujat D., Fiesel F.C., Rothfuss O.C., Kahle P.J., Springer W. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat. Cell Biol. 2010, 12:119-131.
182. Vincow E.S., Merrihew G., Thomas R.E., Shulman N.J., Beyer R.P., MacCoss M.J., Pallanck L.J. The PINK1-Parkin pathway promotes both mitophagy and selective respiratory chain turnover in vivo. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:6400-6405.
183. Dagda R., Zhu J., Kulich S.M., Chu C.T. Mitochondrially localized ERK2 regulates mitophagy and autophagic cell stress: implications for Parkinson's disease. Autophagy 2008, 4:770-782.
184. Naba A., Clauser K.R., Ding H., Whittaker C.A., Carr S.A., Hynes R.O. The extracellular matrix: tools and insights for the "omics" era. Matrix Biol. 2016, (in press).
185. Wang R.C., Wei Y., An Z., Zou Z., Xiao G., Bhagat G., White M., Reichelt J., Levine B. Akt-mediated regulation of autophagy and tumorigenesis through Beclin 1 phosphorylation. Science 2012, 338:956-959.
186. Wei Y., Zou Z., Becker N., Anderson M., Sumpter R., Xiao G., Kinch L., Koduru P., Christudass C.S., Veltri R.W., Grishin N.V., Peyton M., Minna J., Bhagat G., Levine B. EGFR-mediated beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. Cell 2013, 154:1269-1284.
187. Gubbiotti M.A., Neill T., Frey H., Schaefer L., Iozzo R.V. Decorin is an autophagy-inducible proteoglycan and is required for proper in vivo autophagy. Matrix Biol. 2015, (in press).
188. Gubbiotti M.A., Iozzo R.V. Proteoglycans regulate autophagy via outside-in signaling: an emerging new concept. Matrix Biol. 2015, (in press).
189. Douglass S., Goyal A., Iozzo R.V. The role of perlecan and endorepellin in the control of tumor angiogenesis and endothelial cell autophagy. Connect. Tissue Res. 2015, 19:1-11.
190. Ständer M., Naumann U., Dumitrescu L., Heneka M., Löschmann P., Gulbins E., Dichgans J., Weller M. Decorin gene transfer-mediated suppression of TGF-β synthesis abrogates experimental malignant glioma growth in vivo. Gene Ther. 1998, 5:1187-1194.
191. Biglari A., Bataille D., Naumann U., Weller M., Zirger J., Castro M.G., Lowenstein P.R. Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model. Cancer Gene Ther. 2004, 11:721-732.